Biopulse: 5 Stocks Under $10 Worth Watching

(RTTNews) - In this edition of Biopulse, we are featuring 5 biotech stocks trading under $10 that might be worth a look.

1. ASLAN Pharmaceuticals (ASLN)

ASLAN Pharmaceuticals is a clinical stage oncology and immunology focused biopharmaceutical company.

The Company's advanced drug candidate is Varlitinib, which is under a pivotal study in second-line biliary tract cancer, dubbed TreeTopp. The topline data from this study is expected in the second half of 2019.

Also in the pipeline are ASLAN003, under a phase II study in acute myeloid leukemia, and ASLAN004, which has successfully completed a phase I single ascending dose study in moderate to severe atopic dermatitis.

Part 1 readout of the phase II study of ASLAN003 in acute myeloid leukemia is due this quarter.

Shares of ASLAN Pharma have traded in a range of $2.51 to $9.00 in the last 1 year. The stock closed Thursday's (June 27, 2019) trading at $3.07, down 8.36%.

2. Catalyst Biosciences Inc. (CBIO)

Catalyst Bio is a clinical-stage biopharmaceutical company developing novel medicines to address hematology indications.

The Company's lead drug candidate is Marzeptacog alfa (activated) a potent, subcutaneously administered, next-generation Factor VIIa therapy being developed for prophylaxis in hemophilia A or B with inhibitors.

The phase II portion of phase II/III program of Marzeptacog alfa has completed enrollment. Interim data from the trial, reported in February of this year, demonstrated that subcutaneous MarzAA (FVIIa) significantly reduces both annualized bleed rate and the percentage of days with bleeding.

The Company is slated to provide final results for all subjects from the MarzAA phase II trial at the ISTH meeting in July 2019.

Shares of Catalyst Bio are down nearly 47% from their 52-week high of $14.37 recorded on July 16, 2018. The stock closed Thursday's trading at $7.67, up 2.68%.

3. Harrow Health Inc (HROW)

Harrow Health owns a portfolio of healthcare businesses, including ophthalmology pharmaceutical compounding business, ImprimisRx. The Company holds large equity positions in Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, Mayfield Pharmaceuticals and Radley Pharmaceuticals, all companies founded as subsidiaries of Harrow Health.

The Company reported results for the first quarter of 2019 on May 9, 2019.

Net income for the three months ended March 31, 2019 was $11.4 million compared to a loss of $3.5 million in the year-ago quarter. Total revenue for the first quarter of 2019 was $12.3 million compared to $8.86 million in the year-ago period.

Shares of Harrow Health touched a 52-week high of $8.26 in intraday trading on Thursday, before closing at $8.19, up 6.09%.The stock has gained nearly 37 percent so far this month.

4. Neon Therapeutics Inc. (NTGN)

Neon Therapeutics is focused on developing neoantigen-targeted therapies, dedicated to transforming the treatment of cancer.

The Company's most advanced product candidate is NEO-PV-01, a personal neoantigen vaccine, under phase Ib trials, dubbed NT-001, NT-002, NT-003, and NT-004.

NT-001 is exploring the combination of NEO-PV-01 and Bristol Myers' Opdivo in patients with metastatic or advanced melanoma, lung, or bladder cancer. The top-line clinical results, including 12-month follow-up, from this trial are expected in July 2019.

The study dubbed NT-002 is testing the combination of NEO-PV-01 and Merck's Keytruda in patients with advanced or metastatic nonsquamous non-small cell lung carcinoma. The immune monitoring and clinical outcome data from this trial are anticipated by the end of Q3 2020.

NT-003 is evaluating NEO-PV-01 vaccine, either with APX005M or ipilimumab, and nivolumab in patients with advanced or metastatic melanoma. Immune monitoring data is expected in the second half of 2020.

Shares of Neon Therapeutics are down nearly 66% from their 52-week high of $13.51 recorded on July 16, 2018. The stock closed Thursday's trading at $4.65, up 4.73%.

5. Syndax Pharmaceuticals Inc. (SNDX)

Syndax Pharma is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications.

The Company's lead product candidate is Entinostat, which is being developed for advanced hormone receptor positive breast cancer and for multiple solid tumors.

The most advanced clinical trial is E2112, a phase III registration trial of Entinostat plus exemestane in HR+, HER2- breast cancer, which has passed its fourth interim overall survival analysis. The next preplanned analysis is expected in the fourth quarter of this year.

Also in the pipeline are SNDX-5613 and SNDX-6352.

The filing of an Investigational New Drug application with the FDA for SNDX-5613 is due this quarter, with the initiation of a Phase 1 clinical trial in a defined subset of acute leukemias patients expected to follow.

Initial results from a phase I dose escalation trial of SNDX-6352 in patients with chronic graft versus host disease (cGVHD) are expected in the third quarter of 2019.

Shares of Syndax touched a 52-week high of $9.45 on Thursday before closing at $9.05, up 6.35% The stock has gained an impressive 102% year-to-date.